LOGO

Established in 2002, Vaxine is an Australian-based biotechnology company with subsidiaries in Japan and the USA that specialises in development of novel vaccines against a wide range of infectious and chronic diseases. Lead products include novel vaccines against seasonal and pandemic influenza (including 2009 H1N1 - swine flu), Japanese encephalitis, West Nile virus, hepatitis B, malaria, rabies, shigella and insect sting allergy. With funding from the US National Institutes of Health, Vaxine has developed the Advax™ range of polysaccharide vaccine adjuvants, representing a major breakthrough in safe and effective adjuvants suitable for both adult and pediatric use. In 2009, Vaxine was the first company to undertake a clinical trial of the world's first adjuvanted recombinant H1N1/2009 (swine flu) vaccine. This trial not only confirmed the benefits of Advax™ adjuvant technology, but also proved the superiority of new recombinant protein approaches to influenza vaccination manufacture when compared to traditional egg-based production methods.